Background: Upper tract urothelial carcinoma (UTUC) is an aggressive disease with a high progression rate. The standardmanagement for this disease is nephroureterectomy. Nephron sparing nonradical surgery is an alternative therapeutic approach. In men with limited life expectancy, the potential harm of UTUC progression must be weighed against surgical morbidity and mortality, and thus, more conservative approaches may be selected. This study aims to investigate the comparative benefits of radical and conservative surgical management in patients older than 80 years with localized UTUC.
Materials and methods: A search was conducted in the Surveillance, Epidemiology, and End Results database for patients older than 80 years who were diagnosed with localized (T1-2N0M0) cancer in the renal pelvis or ureter as the only malignancy from 2004 to 2015. Patients were divided into 3 therapeutic groups: no surgery, local intervention (ie, local tumor excision or segmented ureterectomy), and radical surgery (nephroureterectomy). Demographic and cancer-related parameter data were collected. Logistic regression analysis was conducted to investigate predictors for surgical treatment. Kaplan-Meier curves and Cox regression were used to analyze survival outcomes.
Results: Data from 774 patients were analyzed, including 205 in the no-surgery group, 181 in the local intervention group, and 388 in the radical surgery group. Older, African American patients with T1 stage disease were less likely to receive surgical treatment. Among surgically treated patients, renal pelvic tumors, and high-grade and T2 stage disease were associated with radical resection. Surgically treated patients had a longer median overall survival (OS) than in those treated nonsurgically (13, 35, and 47 months in no-surgery, local intervention, and radical surgery groups, respectively; p < 0.001). Although surgically treated patients demonstrated higher 5-year OS (8.8% [no surgery], 23.2% [local intervention], and 23.5% [radical surgery], p < 0.001) and 5-year disease-specific survival (DSS) (41.0%[no surgery], 69.1%[local intervention], and 72.9%[radical surgery]; p < 0.001) than in those treated nonsurgically, no significant differences were found between the local intervention and radical surgery groups (p > 0.05). Based on multivariate Cox regression analysis, surgical treatments, including both nonradical and radical resection, were independently associated with improved OS and DSS after controlling for age, marital status, tumor grade, and radiation status.
Conclusions: Patients older than 80 years with localized UTUC who undergo surgery demonstrate longer survival. Radical and nonradical resections seemto have similar OS and DSS outcomes. Thus, when clinically indicated in this population, a more conservative surgical approach may be reasonable.
Acknowledgments
None.
Statement of ethics
Data within the SEER database have previously been deidentified. This study was deemed exempt by the local institutional review board. Informed consent was not applicable. All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Conflicts of interest statement
No conflict of interest has been declared by the authors.
Funding source
No funding to declare.
Author contributions
SW: Data acquisition, quality control of data and algorithms, study design, data analysis and interpretation, statistical analysis, manuscript preparation;
MP: Study design, manuscript review and editing;
MMS: Project supervision, study concept and design, manuscript review and editing.
Data availability
The datasets generated during and/or analyzed during the current study are not publicly available, but are available from the corresponding author on reasonable request.
| [1] |
Woodford R, Ranasinghe W, Aw HC, Sengupta S, Persad R. Trends in incidence and survival for upper tract urothelial cancer (UTUC) in the state of Victoria—Australia. BJU Int 2016; 117(Suppl 4):45-49.
|
| [2] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69(1):7-34.
|
| [3] |
Rouprêt M, Babjuk M, Compérat E, et al. European Association of Urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur Urol 2015; 68(5):868-879.
|
| [4] |
Lughezzani G, Burger M, Margulis V, et al. Prognostic factors in upper urinary tract urothelial carcinomas: A comprehensive review of the current literature. Eur Urol 2012; 62(1):100-114.
|
| [5] |
Raman JD, Messer J, Sielatycki JA, Hollenbeak CS. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973-2005. BJU Int 2011; 107(7):1059-1064.
|
| [6] |
Eylert MF, Hounsome L, Verne J, Bahl A, Jefferies ER, Persad RA. Prognosis is deteriorating for upper tract urothelial cancer: Data for England 1985-2010. BJU Int 2013; 112(2):E107-E113.
|
| [7] |
Rouprêt M, Babjuk M, Compérat E, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol 2018; 73(1):111-122.
|
| [8] |
Flaig TW, Spiess PE, Agarwal N, et al. NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer Version 4.2019. National Comprehensive Cancer Network. Available at: https://www2.tri-kobe.org/nccn/guideline/urological/english/bladder.pdf. Accessed November 26, 2019.
|
| [9] |
Raman JD, Lin YK, Shariat SF, et al. Preoperative nomogram to predict the likelihood of complications after radical nephroureterectomy. BJU Int 2017; 119(2):268-275.
|
| [10] |
Leow JJ, Liu Z, Tan TW, Lee YM, Yeo EK, Chong YL. Optimal management of upper tract urothelial carcinoma: Current perspectives. Onco Targets Ther 2020;13:1-15.
|
| [11] |
Leow JJ, Chong KT, Chang SL, Bellmunt J. Upper tract urothelial carcinoma: A different disease entity in terms of management. ESMO Open 2017; 1(6):e000126.
|
| [12] |
Soria F, Shariat SF, Lerner SP, et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol 2017; 35(3):379-387.
|
| [13] |
Rouprêt M, Hupertan V, Seisen T, et al. Prediction of cancer specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: Development of an optimized postoperative nomogram using decision curve analysis. J Urol 2013; 189(5):1662-1669.
|
| [14] |
Ploussard G, Xylinas E, Lotan Y, et al. Conditional survival after radical nephroureterectomy for upper tract carcinoma. Eur Urol 2015; 67(4):803-812.
|
| [15] |
Brown GA, Busby JE, Wood CG, et al. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int 2006; 98(6):1176-1180.
|
| [16] |
Pak RW, Moskowitz EJ, Bagley DH. What is the cost of maintaining a kidney in upper-tract transitional-cell carcinoma? An objective analysis of cost and survival. J Endourol 2009; 23(3):341-346.
|
| [17] |
Edwards BK, Noone AM, Mariotto AB, et al. Annual report to the nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 2014; 120(9):1290-1314.
|
| [18] |
Lin YK, Deliere A, Lehman K, Harpster LE, Kaag MG, Raman JD. Critical analysis of 30 day complications following radical nephroureterectomy for upper tract urothelial carcinoma. Can J Urol 2014; 21(4):7369-7373.
|
| [19] |
Raman JD, Lin YK, Kaag M, et al. High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy. Urol Oncol 2014; 32(1):47.e9-47.e14.
|
| [20] |
Abouassaly R, Alibhai SM, Shah N, Timilshina N, Fleshner N, Finelli A. Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma. Urology 2010; 76(4):895-901.
|
| [21] |
Inman BA, Tran VT, Fradet Y, Lacombe L. Carcinoma of the upper urinary tract: Predictors of survival and competing causes of mortality. Cancer 2009; 115(13):2853-2862.
|
| [22] |
Seisen T, Peyronnet B, Dominguez-Escrig JL, et al. Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: A systematic review by the EAU non-muscle invasive bladder cancer guidelines panel. Eur Urol 2016; 70(6):1052-1068.
|
| [23] |
Seisen T, Colin P, Rouprêt M. Risk-adapted strategy for the kidney-sparing management of upper tract tumours. Nat Rev Urol 2015; 12(3):155-166.
|
| [24] |
Wu YP, Lin YZ, Lin MY, et al. Risk factors for bladder cancer recurrence survival in patients with upper-tract urothelial carcinoma. Tumori 2018; 104(6):451-458.
|
| [25] |
Yamashita R, Watanabe R, Ito I, et al. Risk factors for intravesical recurrence after nephroureterectomy in patients with upper urinary tract urothelial carcinoma. Int Urol Nephrol 2017; 49(3):425-430.
|
| [26] |
Shigeta K, Kikuchi E, Hagiwara M, et al. The conditional survival with time of intravesical recurrence of upper tract urothelial carcinoma. J Urol 2017; 198(6):1278-1285.
|
| [27] |
Syed JS, Nguyen KA, Suarez-Sarmiento A, et al. Survival outcomes for patients with localised upper tract urothelial carcinoma managed with non-definitive treatment. BJU Int 2018; 121(1):124-129.
|
| [28] |
Lacarrière E, Smaali C, Benyoucef A, Pfister C, Grise P. The efficacy of hemostatic radiotherapy for bladder cancer-related hematuria in patients unfit for surgery. Int Braz J Urol 2013; 39(6):808-816.
|
| [29] |
Liguori G, Amodeo A, Mucelli FP, et al. Intractable haematuria: Long-term results after selective embolization of the internal iliac arteries. BJU Int 2010; 106(4):500-503.
|
| [30] |
Haider AH, Scott VK, Rehman KA, et al. Racial disparities in surgical care and outcomes in the United States: A comprehensive review of patient, provider, and systemic factors. J Am Coll Surg 2013; 216(3):482-492.e12.
|
PDF
(273KB)
